Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer

This study aimed to investigate the significance of HSD3B1 gene status including germline polymorphism and somatic alterations in prostate cancer. Patients with prostate cancer treated with androgen‐deprivation therapy, as well as tissues from metastatic prostate cancer, were included. Genomic DNA was extracted from cancer tissues and whole blood samples, and HSD3B1 (rs1047303, 1245C) was genotyped by Sanger sequencing. The association of HSD3B1 genotype with progression‐free survival according to metastatic volume was examined. Copy number alteration and gene expression of HSD3B1 were examined in prostate cancer cells and public datasets. Among 194 patients, 121 and 73 patients were categorized into low‐ and high‐volume diseases respectively. In multivariate analysis, the adrenal‐permissive genotype (AC/CC) was significantly associated with increased risk of progression compared with the adrenal‐restrictive genotype (AA) in low volume, but not high‐volume diseases. Somatic mutation in HSD3B1 was detected at least in two cases of castration‐resistant prostate cancer tissues. HSD3B1 amplification and overexpression were detected in castration‐resistant prostate cancer cells and tissues. The current findings suggest that both germline and somatic alterations of HSD3B1 may cooperatively promote castration resistance in prostate cancer and HSD3B1 as a promising biomarker for precision medicine, warranting further investigations.

[1]  Y. Oda,et al.  Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression , 2020, Cancer science.

[2]  M. Gleave,et al.  HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  W. Isaacs,et al.  Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  R. DiPaola,et al.  HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. , 2020, JAMA oncology.

[5]  M. Loda,et al.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.

[6]  M. Shiota,et al.  Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy , 2019, The Prostate.

[7]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[8]  T. Sumiyoshi,et al.  Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone , 2019, JAMA network open.

[9]  S. Upadhyay,et al.  HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer , 2018, The Journal of clinical investigation.

[10]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[11]  T. Friedlander,et al.  HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer , 2017, JAMA oncology.

[12]  P. Kantoff,et al.  Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer , 2017, JAMA oncology.

[13]  L. Cannon-Albright,et al.  Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer , 2017, JAMA oncology.

[14]  Zachary J. Heins,et al.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. , 2017, JCO precision oncology.

[15]  T. Uchiumi,et al.  Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Tindall,et al.  HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. , 2016, The Lancet. Oncology.

[17]  Y. Oda,et al.  Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. , 2016, Journal of the National Cancer Institute.

[18]  M. Shiota,et al.  Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer , 2016, International journal of urology : official journal of the Japanese Urological Association.

[19]  M. Taguri,et al.  Low serum dehydroepiandrosterone examined by liquid chromatography‐tandem mass spectrometry correlates with poor prognosis in hormone‐naïve prostate cancer , 2016, The Prostate.

[20]  T. Uchiumi,et al.  SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy. , 2015, European journal of cancer.

[21]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[22]  Dustin R. Bunch,et al.  Conversion of abiraterone to D4A drives antitumor activity in prostate cancer , 2015, Nature.

[23]  P. Nelson,et al.  A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer , 2013, Cell.

[24]  M. Gleave,et al.  A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[25]  Seiji Naito,et al.  Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. , 2012, Endocrine-related cancer.

[26]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[27]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[28]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[29]  K. Izumi,et al.  Adrenal androgen levels as predictors of outcome in castration‐resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second‐line anti‐androgen , 2010, International journal of urology : official journal of the Japanese Urological Association.

[30]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[31]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[32]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jacques Simard,et al.  Molecular Biology of the 3-Hydroxysteroid Dehydrogenase/5-4 Isomerase Gene Family , 2005 .

[34]  H. Fujita,et al.  The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor , 2004, Cancer Research.

[35]  Jacques Simard,et al.  Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. , 2005, Endocrine reviews.